Citations

Showing 10 of 107964 citations.

Spinal subdural empyema: A two-dimensional illustrative operative video
Michaelides, Loizos , Patel, Saarang, Edgar, Mark , Chen, Selby , Lee, Seung-Jin, Edgar, Mark A. , Sandhu, Sukhwinder, Lee, Seung Jin , Patel, Saarang , Gendreau, Julian , Brown, Nolan J. , Clifton, William , Sandhu, Sukhwinder J.S.

Mayo Clinic

Surgical Neurology International | March 21, 2025 | Volume: 16 | Issue: No issue available | Pages: 95

10.25259/sni_141_2025 | PMID 40206764 Get It

Background Spinal subdural empyema rarely involves the spinal cord and may result in devastating neurological deficits. These lesions typically require prompt diagnosis, surgical evacuation, and antibiotic therapy. Here, we present the clinical course, imaging, and narrated operative video of a thoracic spinal subdural empyema initially diagnosed as an intramedullary neoplasm. Case Description A 73-year-old female presented with a 6-month history of worsening thoracic myelopathy; over the last few weeks, she rapidly developed paraplegia. She was initially diagnosed with an enlarging thoracic intramedullary mass. A spinal biopsy was performed for the presumptive diagnosis of primary intramedullary central nervous system lymphoma. However, at surgery, the thoracic lesion proved to be a chronic subdural empyema (i.e., surrounded by arachnoid granulations and soft-purulent tissue). Interestingly, the operative specimen failed to grow any specific organism. Conclusion Spinal subdural empyema should be one of the differential diagnoses considered for patients presenting with intradural spinal cord lesions.
Fungal Pericarditis—A Systematic Review of 101 Cases
Jancic, Predrag , Milutinovic, Stefan , Ward, Marshall , Radovanovic, Milan , Jovanovic, Nikola , Antic, Marina , Nikolajevic, Nikola , Petrović, Marija , Jevtic, Dorde , Adam, Adam , Dumic, Igor , Dumic, Igor , Jevtic, Djordje

Mayo Clinic

Microorganisms | March 21, 2025 | Volume: 13 | Issue: 4 | Pages: 707

10.3390/microorganisms13040707 | PMID 40284544 Get It

Fungal pericarditis is a rare disease but its incidence has risen in parallel with the global increase in invasive fungal infections. This systematic review analyzes data from previously reported cases of fungal pericarditis to provide an improved understanding of the etiology, clinical presentation, management, and outcomes of this rare disease. We reviewed Medline and Scopus databases from 1 January 1990 to 29 January 2024 for case reports that documented the isolation of a fungal pathogen from pericardial fluid or tissue. Of the 2330 articles screened, 101 cases met the inclusion criteria. Patients with fungal pericarditis and the involvement of at least one other organ—usually the lungs, brain, or kidney—had worse outcomes than patients with isolated pericardial disease. Immunosuppression was reported in 50% of cases and was associated with worse outcomes in adults. Patients who presented with chest pain, received adequate empiric antifungal therapy, and underwent pericardiocentesis and pericardiectomy had improved survival. The most common isolated pathogens were Candida spp., followed by Aspergillus spp. and Mucor spp., with the latter two linked to worse outcomes. Only 35% of patients received empiric antifungal medications before the causative pathogen was identified, and mortality was associated with a delay in appropriate therapy. Immunosuppression, disseminated disease, and presence of shock/multiorgan failure were additional risk factors associated with death. Fungal pericarditis carries a mortality rate of up to 50%, with nearly half of patients being immunocompromised. Clinicians frequently do not consider fungal pericarditis in the differential diagnoses, which leads to delays in treatment and poorer outcomes. Further prospective multicenter studies are urgently needed to better understand the epidemiology, improve diagnostic testing and management, and decrease unacceptably high mortality in patients with fungal pericarditis.
Germline Genetic Testing in Patients with Bone and Soft Tissue Sarcoma: A Prospective Multicenter Study to Evaluate Cancer Susceptibility
Ailts, Isaak , Golafshar, Michael A. , Kunze, Katie L. , Klint, Margaret, Barrus, Kathleen , Nussbaum, Robert L., Esplin, Edward D. , Leach, Brandie, Nielsen, Sarah M. , Samadder, N. Jewel , Seetharam, ­Mahesh , Young, Sarah , Golafshar, Michael , Esplin, Edward D , Kunze, Katie L , Leach, Brandie

Mayo Clinic

International Journal of Molecular Sciences | March 21, 2025 | Volume: 26 | Issue: 7 | Pages: 2839

10.3390/ijms26072839 | PMID 40243416 Get It

Sarcomas are rare heterogenous mesenchymal tumors with over seventy-five different subtypes, with varying biology and outcomes, with no clear inciting factor in the vast majority. To determine the prevalence of pathogenic germline variants (PGV) in patients with sarcomas, we undertook a prospective multi-site study of germline sequencing using an 84-gene next-generation sequencing panel among patients receiving care at the four Mayo Clinic Cancer Centers. Of 115 patients with bone and soft tissue sarcoma, the median age was 60 years, 49.6% were female, 82.6% were White. The anatomical location of the primary tumor included extremities (34.8%), retroperitoneum (19.1%), trunk (13.0%), and head and neck (7.8%). Family history of cancer was present in 62.6% of the study population. Ten patients (8.7%) had a pathogenic/likely pathogenic variant (PGV). Of these, three had stage IV sarcoma, and seven had earlier-stage sarcoma (stages I–III). Among the 55 (48.7%) patients who had variant of uncertain significance (VUS), 41.1% (22/55) had stage IV sarcoma and 58.9% (33/55) had earlier-stage disease. Of the ten patients with PGV, high-to-moderate penetrance gene abnormalities were identified in eight patients (80%) involving TP53 (3), BRCA1 (1), SDHA (1), ATM (2), and NBN (1) genes. The vast majority of the PGVs (70%) would not have been detected using the current guidelines. Because of the paucity of sarcomas and lack of effective treatment options for advanced disease, germline testing in sarcomas represents a potentially impactful strategy to assess therapeutic options and for assessment of familial risk.
Utility of Cardiac CT for Cardiomyopathy Phenotyping
Ibrahim, Ramzi, Abdelnabi, Mahmoud , Pathangey, Girish , Farina, Juan M. , Lester, Steven J., Ayoub, Chadi , Alsidawi, Said , Tamarappoo, Balaji , Jokerst, Clinton, Arsanjani, Reza , Farina, Juan M , Tamarappoo, Balaji K, Arsanjani, Reza , Alsidawi, Said , Pathangey, Girish , Ibrahim, Ramzi

Mayo Clinic

Tomography | March 21, 2025 | Volume: 11 | Issue: 3 | Pages: 39

10.3390/tomography11030039 | PMID 40137579 Get It

Cardiac computed tomography (CT) has rapidly advanced, becoming an invaluable tool for diagnosing and prognosticating various cardiovascular diseases. While echocardiography and cardiac magnetic resonance imaging (CMR) remain the gold standards for myocardial assessment, modern CT technologies offer enhanced spatial resolution, making it an essential tool in clinical practice. Cardiac CT has expanded beyond coronary artery disease evaluation, now playing a key role in assessing cardiomyopathies and structural heart diseases. Innovations like photon-counting CT enable precise estimation of myocardial extracellular volume, facilitating the detection of infiltrative disorders and myocardial fibrosis. Additionally, CT-based myocardial strain analysis allows for the classification of impaired myocardial contractility, while quantifying cardiac volumes and function remains crucial in cardiomyopathy evaluation. This review explores the emerging role of cardiac CT in cardiomyopathy phenotyping, emphasizing recent technological advancements.
A Validity Analysis of Text-to-Image Generative Artificial Intelligence Models for Craniofacial Anatomy Illustration
Haider, Syed Ali , Gomez-Cabello, Cesar A. , Borna, Sahar , Pressman, Sophia M. , Genovese, Ariana , Trabilsy, Maissa , Galvao, Andrea , Murray, Peter M. , Parte, Yogesh, Yu, Yunguo , Tao, Cui , Forte, Antonio J. , Gomez-Cabello, Cesar A , Borna, Sahar , Galvao, Andrea , Tao, Cui , Forte, Antonio Jorge , Pressman, Sophia , Haider, Syed A , Genovese, Ariana , Prabha, Srinivasagam , Aziz, Keith T

Mayo Clinic

Journal of Clinical Medicine | March 21, 2025 | Volume: 14 | Issue: 7 | Pages: 2136

10.3390/jcm14072136 | PMID 40217587 Get It

Background: Anatomically accurate illustrations are imperative in medical education, serving as crucial tools to facilitate comprehension of complex anatomical structures. While traditional illustration methods involving human artists remain the gold standard, the rapid advancement of Generative Artificial Intelligence (GAI) models presents a new opportunity to automate and accelerate this process. This study evaluated the potential of GAI models to produce craniofacial anatomy illustrations for educational purposes. Methods: Four GAI models, including Midjourney v6.0, DALL-E 3, Gemini Ultra 1.0, and Stable Diffusion 2.0 were used to generate 736 images across multiple views of surface anatomy, bones, muscles, blood vessels, and nerves of the cranium in both oil painting and realistic photograph styles. Four reviewers evaluated the images for anatomical detail, aesthetic quality, usability, and cost-effectiveness. Inter-rater reliability analysis assessed evaluation consistency. Results: Midjourney v6.0 scored highest for aesthetic quality and cost-effectiveness, and DALL-E 3 performed best for anatomical detail and usability. The inter-rater reliability analysis demonstrated a high level of agreement among reviewers (ICC = 0.858, 95% CI). However, all models showed significant flaws in depicting crucial anatomical details such as foramina, suture lines, muscular origins/insertions, and neurovascular structures. These limitations were further characterized by abstract depictions, mixing of layers, shadowing, abnormal muscle arrangements, and labeling errors. Conclusions: These findings highlight GAI’s potential for rapidly creating craniofacial anatomy illustrations but also its current limitations due to inadequate training data and incomplete understanding of complex anatomy. Refining these models through precise training data and expert feedback is vital. Ethical considerations, such as potential biases, copyright challenges, and the risks of propagating inaccurate information, must also be carefully navigated. Further refinement of GAI models and ethical safeguards are essential for safe use.
Antimicrobial Performance of a Novel Drug-Eluting Bioenvelope
Garrigos, Zerelda Esquer , Kapur, Sunil , Williams, Michelle LeRoux , Sohail, M. Rizwan , Sohail, M Rizwan

Mayo Clinic

Antibiotics | March 21, 2025 | Volume: 14 | Issue: 4 | Pages: 330

10.3390/antibiotics14040330 | PMID 40298472 Get It

Background: Preventing infections associated with cardiac implantable electronic devices (CIED) and neurostimulators is essential to optimizing patient outcomes. This study aimed to evaluate the antimicrobial performance of a biologic CIED envelope incorporating a bioabsorbable disc infused with rifampin and minocycline. Methods: The antimicrobial activity was evaluated in a rabbit model and in vitro elution tests. Based on in vivo–in vitro correlation studies, a modified AATCC-100 method was used to quantitatively assess antibacterial activity across seven bacterial strains relevant to CIED infections. Results: Pharmacokinetic analysis showed a biphasic elution profile, with rapid initial release followed by more gradual elution over 14 days. The AATCC results showed no bacterial recovery for any tested species, with complete eradication in all replicates. Conclusions: These results support the use of antibiotic-eluting bioenvelopes as an effective strategy for preventing bacterial infections associated with CIED. The modified AATCC-100 test and in vivo–in vitro correlation studies provide new tools for the evaluation of the antibiotic activity of implantable biomaterials.
Outcomes of Left Atrial Appendage Occlusion with Atrial Fibrillation Ablation: A real-world analysis from the National Inpatient Sample database
Khan, Muhammad Zia, Devera, Justin , Alruwaili, Waleed , Naveed, Muhammad Abdullah, Hakim, Yaseen Maqsood, Leon, William, Nguyen, Amanda , Asad, Zain Ul Abideen , Khan, Samrina, Gonuguntla, Karthik , Ice, Daniel, Asad, Zain Ul Abideen , Khan, Muhammad Zia , Agarwal, Siddharth, Khan, Samrina, Munir, Muhammad Bilal

Mayo Clinic

No container title available | March 21, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.174252964.42947477/v1 Get It

Background: The safety and cost of concomitant atrial fibrillation (AF) ablation and left atrial appendage occlusion (LAAO) procedure remain unknown. Objective: The study sought to determine real-world outcomes of AF patients who underwent LAAO with ablation. Methods: The National Inpatient Sample and International Classification of Diseases–Tenth Revision codes were used to identify patients who underwent LAAO with and without AF ablation during the years 2016-2022. The outcomes assessed included procedural complications and resource utilization. Results: LAAO with AF ablation was associated with a higher rate of overall complications (odds ratio [OR] 1.54, 95% confidence interval [CI] 1.37-1.74), major complications (OR 1.38, 95% CI 1.18-1.60), non-home discharge (OR 1.55, 95% CI 1.23-1.96), prolonged length of stay >1 day (OR 3.21, 95% CI 2.92-3.52), and increased hospitalization costs as defined by median cost >$25,926 (OR 19.42, 95% CI 16.21-23.25) when compared to LAAO alone after adjustment for potential confounding variables. Patients who underwent LAAO with ablation were also more likely to receive pacemaker implantation (3.6 % vs 0.2%, P < 0.001) and experience acute kidney injury (3.9% vs 2.1%, P < 0.001) and non-ST elevation myocardial infarction (3.7% vs 1.5%, P < 0.001). Conclusion: In a large, contemporary, real-world study of LAAO procedures in the United States, concomitant AF ablation was associated with a higher rate of overall and major complications and an increased resource utilization.
Going Back Home: Understanding the Challenges and Discrimination of Early and Mid-Career International and Puerto Rican Medical Graduates in Oncology Fields in the United States
Olazagasti, Coral , Celi, Claudia Villa , Mahtani, Arun , Velázquez, Ana I. , Sridhar, Arthi , Horiguchi, Miki , González, Mariana , Bernabe, Carolina , Abioye, Oyepeju , Dizman, Nazlı , Kiel, Lauren , Horiguchi, Miki , Gonzalez, Mariana , Bernabe, Carolina , Abioye, Oyepeju , Dizman, Nazli , Duma, Narjust , Velazquez, Ana I , Villa Celi, Claudia S , Kiel, Lauren , Florez, Narjust

Mayo Clinic

JCO Global Oncology | March 20, 2025 | Volume: No volume available | Issue: 11 | Pages: No page available

10.1200/go-24-00513 | PMID 40112258 Get It

PURPOSE Although international medical graduates (IMGs) and Puerto Rican Medical Graduates (PRMGs) comprise an integral part of the health care workforce, these individuals, particularly women, frequently face numerous types of discrimination throughout medical training and independent practice. To our knowledge, we conducted the first cross-sectional study to understand the journeys and consequences of migration faced by IMGs and PRMGs in the US oncology workforce. METHODS We developed a cross-sectional, online survey consisting of 51 multiple choice and open-ended questions that captured demographic information, professional status, period of migration to the United States, location within the United States that participants migrated to, reasons for migration, cultural adaptation, experiences of discrimination during training, and overall professional experiences in the United States. RESULTS The majority of participants cited better education, professional gains, and a lack of opportunities in participants' home country as primary reasons for migration to the United States. However, most participants, particularly women, experienced staunch assimilation to fit the mold of professional American standards; women were also particularly likely to report experiences of racial/ethnic, language, and gender discrimination during oncology training in the United States, which only marginally improved during independent practice. Despite such discrimination, most participants reported excellent professional satisfaction during training and independent practice, although only moderate personal satisfaction. Most participants decided to stay in the United States, citing reasons pertaining to enhanced professional opportunities, whereas those that returned home valued reasons relating to family and quality of life. CONCLUSION Our sobering findings underscore the need for institutional enforcement of an inclusive environment encompassing cultural humility, enactment of programs addressing barriers to socialization, immigration laws, and financial support, creation of IMG-specific support networks, and the sponsorship and promoting of minority women physicians.
Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer
Bari, Shahla , Matejcic, Marco , Xie, Hao , Teer, Jamie K. , Felder, Seth , Schmit, Stephanie L. , Kim, Richard D. , Şahin, İbrahim Halil , Powers, Benjamin D. , Chan, Timothy An-thy

Mayo Clinic

JAMA Network Open | March 20, 2025 | Volume: 8 | Issue: 3 | Pages: e251186

10.1001/jamanetworkopen.2025.1186 | PMID 40111368 Get It

ImportanceImmune checkpoint inhibitors (ICIs) have been approved for treatment of microsatellite instable (MSI-H) metastatic colorectal cancer (mCRC), but factors associated with receipt and efficacy of ICIs in routine clinical practice remain largely unknown.ObjectiveTo identify factors associated with receipt of ICIs and associated survival outcomes among patients with mCRC in routine clinical practice.Design, Setting, and ParticipantsThis population-based cohort study used deidentified data from a nationwide electronic health record–derived database to include 18 932 patients diagnosed with mCRC between January 2013 and June 2019. Population-based patients were diagnosed with de novo mCRC and had at least 2 documented clinical visits on or after the date of diagnosis. The study analyses were performed between September 2020 and April 2021.ExposurePatients received ICI therapy and/or chemotherapy as part of a systemic treatment for mCRC.Main Outcomes and MeasuresThe outcomes were receipt of ICI therapy, overall survival (OS), and time to treatment discontinuation (TTD).ResultsIn this cohort study of 18 932 patients diagnosed with mCRC (10 537 [55.7%] male; 546 [2.9%] Asian, 2005 [10.6%] Black or African American, 1674 [8.8%] Hispanic, 12 338 [65.2%] White, 4043 [21.4%] unknown race or ethnicity; median [IQR] age at metastatic diagnosis, 64.6 [55.0-73.3] years), patients with MSI-H tumors had a significantly higher probability of receiving ICIs than those with microsatellite stable (MSS) tumors (odds ratio [OR], 22.66 [95% CI, 17.30-29.73]; P &amp;lt; .001), whereas patients initially diagnosed with synchronous mCRC had significantly lower odds of receiving ICIs than patients with metachronous mCRC (OR, 0.57 [95% CI, 0.45-0.73]; P &amp;lt; .001). Patients with MSI-H tumors who received ICIs as first line of therapy had significantly longer OS than those receiving chemotherapy only (HR, 0.37 [95% CI, 0.25-0.56]; P &amp;lt; .001). Among patients with MSS tumors, ICI-based therapy was associated with significantly longer OS for patients with high albumin level (vs low: HR, 0.28 [95% CI, 0.18-0.45]; P &amp;lt; .001) and antibiotic use (vs nonuse: HR, 0.43 [95% CI, 0.27-0.67]; P &amp;lt; .001), but a significantly shorter OS for patients with synchronous mCRC (vs metachronous: HR, 1.90 [95% CI, 1.24-2.89]; P = .003). In addition, 29 out of 235 patients with MSS tumors (12.3%) experienced durable responses on ICI-based therapy. Similar patterns of associations with TTD were observed.Conclusions and RelevanceIn this cohort study of patients with mCRC, clinical characteristics were associated with different survival outcomes in patients treated with ICI-based therapy, with important clinical implications for patients with MSS tumors who are generally unresponsive to immunotherapy.